| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Townsend Richard Nolan | Chief Executive Officer, Director | C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK | /s/ Youjin Choi, Attorney-in-Fact | 17 Oct 2025 | 0001995218 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | LXEO | Common Stock | Award | $0 | +33,000 | +15% | $0.000000 | 255,251 | 15 Oct 2025 | Direct | |
| transaction | LXEO | Common Stock | Sale | $116,021 | -12,985 | -5.1% | $8.94 | 242,266 | 17 Oct 2025 | Direct | F1, F2 |
| transaction | LXEO | Common Stock | Sale | $1,415 | -148 | -0.06% | $9.56 | 242,118 | 17 Oct 2025 | Direct | F1, F3, F4 |
| Id | Content |
|---|---|
| F1 | Represents a sale to cover tax obligations on the release of Restricted Stock Units ("RSUs"). |
| F2 | This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F3 | This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F4 | Includes 131,092 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. |